Our analysis confirmed lower than expected rates in the use of beta-blockers and mineralocorticoid receptor agonists (MRA) as baseline treatment, which may be due to the high number of patients diagnosed with de novo HF (> 30%). This evidence concerns the gene NR3C2 and hydrops fetalis.